NCT07039201View on ClinicalTrials.gov

A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)

NANot yet recruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

July 31, 2027

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Interventions

BIOLOGICAL

CG-102-12C

Chimeric Antigen Receptor Autologous T-cell

Trial Locations (1)

310003

First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou

Sponsors

Collaborators (1)

Cells & Genes Biotech

All Listed Sponsors

collaborator

Cells & Genes Biotech

UNKNOWN

lead

Zhejiang University

OTHER

NCT07039201 - A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter